Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Radiotherapy in Elderly Esophageal Cancer
NCT05817201Phase 3Unknown
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in esophageal cancer (2 arms), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05817201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817201.